Version 1
: Received: 22 February 2023 / Approved: 3 March 2023 / Online: 3 March 2023 (08:30:15 CET)
How to cite:
Sadat Larijani, M.; Doroud, D.; Banifazl, M.; Karami, A.; Bavand, A.; Ashrafian, F.; Ramezani, A. A Landscape on Disorders Following Different COVID-19 Vaccination: A Systematic Review of Iranian Case Reports. Preprints2023, 2023030061. https://doi.org/10.20944/preprints202303.0061.v1.
Sadat Larijani, M.; Doroud, D.; Banifazl, M.; Karami, A.; Bavand, A.; Ashrafian, F.; Ramezani, A. A Landscape on Disorders Following Different COVID-19 Vaccination: A Systematic Review of Iranian Case Reports. Preprints 2023, 2023030061. https://doi.org/10.20944/preprints202303.0061.v1.
Cite as:
Sadat Larijani, M.; Doroud, D.; Banifazl, M.; Karami, A.; Bavand, A.; Ashrafian, F.; Ramezani, A. A Landscape on Disorders Following Different COVID-19 Vaccination: A Systematic Review of Iranian Case Reports. Preprints2023, 2023030061. https://doi.org/10.20944/preprints202303.0061.v1.
Sadat Larijani, M.; Doroud, D.; Banifazl, M.; Karami, A.; Bavand, A.; Ashrafian, F.; Ramezani, A. A Landscape on Disorders Following Different COVID-19 Vaccination: A Systematic Review of Iranian Case Reports. Preprints 2023, 2023030061. https://doi.org/10.20944/preprints202303.0061.v1.
Abstract
Vaccination against SARS-CoV-2 has significantly contributed to the recent pandemic control. COVID-19 vaccines are available with different platforms and the primary clinical trials results presented acceptable safety profile of the approved vaccines. Nevertheless, the long-term assessment of the adverse events or rare conditions need to be investigated. The present systematic review, aimed at classification of Iranian case reports following COVID-19 immunization. To achieve this goal, the related published case reports were explored via PubMed, Web of Science and Google scholar according to PRISMA guideline and available up to 14th Dec, 2022. Out of 437 explored studies, the relevant data were fully investigated which totally led to 40 studies including 64 case reports with a new onset of a problem. The cases were then classified according to the various items such as the type of adverse event manifestations and COVID-19 vaccine.
The reported COVID-19 vaccines in the studied cases included Sinopharm, AstraZeneca, and COVAXIN. The results showed that the adverse events presented in 8 different categories from which cutaneous problems accounted as the most prevalent manifestations (43.7%) in which rare diseases were also screened such as Steven-Johnson syndrome, Morphea and Toxic Epidermal Necrolysis. Notably, almost 60% of the cases had no comorbidities. Moreover, the obtained data revealed nearly half of the incidences occurred after the first dose of injection and the mean duration of improvement after the symptom onset was 18.72±24.69 days. 73% of all the cases were either significantly improved or fully recovered. Although the advantages of COVID-19 vaccination is undoubtedly significant, the high risk individuals including those with a history of serious disease or comorbidities immunodeficiency conditions should be vaccinated with the utmost caution.
Keywords
COVID-19; Vaccination; Adverse event; Case report; Iran
Subject
MEDICINE & PHARMACOLOGY, Pathology & Pathobiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
*
